Caroline C. Ennis

Ms. Caroline C. Ennis

Clemson University
+1
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Gene
Verified
Journal Article
Closed access
CECaroline C. Ennis
Caroline C. Ennis
NHNariah N. Haeffner
Nariah N. Haeffner
CKCameron D. Keyser
Cameron D. Keyser
SLShannon T. Leonard
Shannon T. Leonard
AMAustin C. Macdonald-Shedd
Austin C. Macdonald-Shedd
JBJuan Antonio Baeza
Juan Antonio Baeza

26 September 2021 in Diseases
Verified
Journal Article
Open access
PDF file
Cassandra Millet-BoureimaCassandra Millet-Boureima
Cassandra Millet-Boureima
CECaroline C. Ennis
Caroline C. Ennis
JJJurnee Jamison
Jurnee Jamison
SMShana McSweeney
Shana McSweeney
APAnna Park
Anna Park
CGChiara Gamberi
Chiara Gamberi
Melatonin functions as a central regulator of cell and organismal function as well as a neurohormone involved in several processes, e.g., the regulation of the circadian rhythm, sleep, aging, oxidative response, and more. As such, it holds immense pharmacological potential. Receptor-mediated melatonin function mainly occurs through MT1 and MT2, conserved amongst mammals. Other melatonin-binding proteins exist. Non-receptor-mediated activities involve regulating the mitochondrial function and antioxidant cascade, which are frequently affected by normal aging as well as disease. Several pathologies display diseased or dysfunctional mitochondria, suggesting melatonin may be used therapeutically. Drosophila models have extensively been employed to study disease pathogenesis and discover new drugs. Here, we review the multiple functions of melatonin through the lens of functional conservation and model organism research to empower potential melatonin therapeutics to treat neurodegenerative and renal diseases.